Astex Pharmaceuticals, Inc. clinical trials

Acquired by Otsuka Holdings Co., Ltd., Oct 11, 2013 · source ↗

The registry lists 45 studies whose lead sponsor is Astex Pharmaceuticals, Inc.. 0 are recruiting or about to start. Per ClinicalTrials.gov, last updated Jan 23, 2025.

Studies

Recruiting first, then most recently updated. Showing 45 of 45. All Otsuka Holdings Co., Ltd. studies →

• SGI-110 in Participants With Myelodysplastic Syndromes (MDS) or Acute Myelogenous Leukemia (AML)CompletedNCT01261312Phase 1/2

  Sponsor listed in the registry: Astex Pharmaceuticals, Inc. · First submitted before Astex Pharmaceuticals, Inc. became part of Otsuka Holdings Co., Ltd.

• A Study of Oral Decitabine/Cedazuridine in Combination With Magrolimab in Participants With Intermediate- to Very High-Risk Myelodysplastic Syndromes (MDS)TerminatedNCT05835011Phase 2

  Sponsor listed in the registry: Astex Pharmaceuticals, Inc. · First submitted after Astex Pharmaceuticals, Inc. became part of Otsuka Holdings Co., Ltd.

• Phase 3 Randomized, Open-Label Study of Guadecitabine vs Treatment Choice in Previously Treated Acute Myeloid LeukemiaCompletedNCT02920008Phase 3

  Sponsor listed in the registry: Astex Pharmaceuticals, Inc. · First submitted after Astex Pharmaceuticals, Inc. became part of Otsuka Holdings Co., Ltd.

• SGI-110 in Adults With Untreated Acute Myeloid Leukemia (AML), Not Considered Candidates for Intensive Remission InductionCompletedNCT02348489Phase 3

  Sponsor listed in the registry: Astex Pharmaceuticals, Inc. · First submitted after Astex Pharmaceuticals, Inc. became part of Otsuka Holdings Co., Ltd.

• Guadecitabine Extension StudyTerminatedNCT03603964Phase 2

  Sponsor listed in the registry: Astex Pharmaceuticals, Inc. · First submitted after Astex Pharmaceuticals, Inc. became part of Otsuka Holdings Co., Ltd.

• Guadecitabine (SGI-110) vs Treatment Choice in Adults With MDS or CMML Previously Treated With HMAsCompletedNCT02907359Phase 3

  Sponsor listed in the registry: Astex Pharmaceuticals, Inc. · First submitted after Astex Pharmaceuticals, Inc. became part of Otsuka Holdings Co., Ltd.

• SGI-110 in Combination With Carboplatin in Ovarian CancerCompletedNCT01696032Phase 2

  Sponsor listed in the registry: Astex Pharmaceuticals, Inc. · First submitted before Astex Pharmaceuticals, Inc. became part of Otsuka Holdings Co., Ltd.

• Study of ASTX727 vs IV Decitabine in Participants With MDS, CMML, and AMLCompletedNCT03306264Phase 3

  Sponsor listed in the registry: Astex Pharmaceuticals, Inc. · First submitted after Astex Pharmaceuticals, Inc. became part of Otsuka Holdings Co., Ltd.

• SGI-110 in the Treatment of Advanced Hepatocellular Carcinoma (HCC)CompletedNCT01752933Phase 2

  Sponsor listed in the registry: Astex Pharmaceuticals, Inc. · First submitted before Astex Pharmaceuticals, Inc. became part of Otsuka Holdings Co., Ltd.

• Pharmacokinetic Guided Dose Escalation and Dose Confirmation With Oral Decitabine and Oral Cytidine Deaminase Inhibitor (CDAi) in Patients With Myelodysplastic Syndromes (MDS)CompletedNCT02103478Phase 1/2

  Sponsor listed in the registry: Astex Pharmaceuticals, Inc. · First submitted after Astex Pharmaceuticals, Inc. became part of Otsuka Holdings Co., Ltd.

• A Study of ASTX660 as a Single Agent and in Combination With ASTX727 in Subjects With Relapsed/Refractory Acute Myeloid Leukemia (AML)TerminatedNCT04155580Phase 1

  Sponsor listed in the registry: Astex Pharmaceuticals, Inc. · First submitted after Astex Pharmaceuticals, Inc. became part of Otsuka Holdings Co., Ltd.

• Dose-finding Study Using Pentostatin for Injection in the Treatment of Steroid-refractory aGvHDTerminatedNCT00032773Phase 1/2

  Sponsor listed in the registry: Astex Pharmaceuticals, Inc. · First submitted before Astex Pharmaceuticals, Inc. became part of Otsuka Holdings Co., Ltd.

• Safety Study to Determine the Maximum Tolerated Dose, Pharmacokinetics and Pharmacodynamics of Oral MP470, a Multitargeted Tyrosine Kinase Inhibitor, in Patients With Solid MalignanciesCompletedNCT00894894Phase 1

  Sponsor listed in the registry: Astex Pharmaceuticals, Inc. · First submitted before Astex Pharmaceuticals, Inc. became part of Otsuka Holdings Co., Ltd.

• Safety of MP470 in Combination With Standard-of-Care Chemotherapy Regimens to Treat Solid TumorsCompletedNCT00881166Phase 1

  Sponsor listed in the registry: Astex Pharmaceuticals, Inc. · First submitted before Astex Pharmaceuticals, Inc. became part of Otsuka Holdings Co., Ltd.

• A Study of HSP90 Inhibitor AT13387 Alone or in Combination With Abiraterone AcetateCompletedNCT01685268Phase 1/2

  Sponsor listed in the registry: Astex Pharmaceuticals, Inc. · First submitted before Astex Pharmaceuticals, Inc. became part of Otsuka Holdings Co., Ltd.

• Safety of SGI-1776, A PIM Kinase Inhibitor in Refractory Prostate Cancer and Relapsed/Refractory Non Hodgkin's LymphomaTerminatedNCT00848601Phase 1

  Sponsor listed in the registry: Astex Pharmaceuticals, Inc. · First submitted before Astex Pharmaceuticals, Inc. became part of Otsuka Holdings Co., Ltd.

• A Study to Investigate the Effect of CYP3A4 Inhibition on the Single Dose Pharmacokinetics of ASTX660 and the Effect of a Single Dose of ASTX660 on the Pharmacokinetics of the CYP3A4 Substrate MidazolamCompletedNCT04411030Phase 1

  Sponsor listed in the registry: Astex Pharmaceuticals, Inc. · First submitted after Astex Pharmaceuticals, Inc. became part of Otsuka Holdings Co., Ltd.

• Effect of Food on Blood Levels of ASTX727CompletedNCT03813186Phase 1

  Sponsor listed in the registry: Astex Pharmaceuticals, Inc. · First submitted after Astex Pharmaceuticals, Inc. became part of Otsuka Holdings Co., Ltd.

• A Phase 2, Open-Label Study of Amuvatinib in Combination With Platinum-Etoposide Chemotherapy in Small Cell Lung CancerCompletedNCT01357395Phase 2

  Sponsor listed in the registry: Astex Pharmaceuticals, Inc. · First submitted before Astex Pharmaceuticals, Inc. became part of Otsuka Holdings Co., Ltd.

• Decitabine Versus Supportive Care in Adults With Advanced-stage MDSCompletedNCT00043381Phase 3

  Sponsor listed in the registry: Astex Pharmaceuticals, Inc. · First submitted before Astex Pharmaceuticals, Inc. became part of Otsuka Holdings Co., Ltd.

• Thorough QT Assessment of Cedazuridine in Healthy SubjectsCompletedNCT04953923Phase 1

  Sponsor listed in the registry: Astex Pharmaceuticals, Inc. · First submitted after Astex Pharmaceuticals, Inc. became part of Otsuka Holdings Co., Ltd.

• A Study of AT13387 in Patients With Non-Small Cell Lung Cancer (NSCLC) Alone and in Combination With CrizotinibCompletedNCT01712217Phase 1/2

  Sponsor listed in the registry: Astex Pharmaceuticals, Inc. · First submitted before Astex Pharmaceuticals, Inc. became part of Otsuka Holdings Co., Ltd.

• Study of Rubitecan in Cancer Patients With Renal or Hepatic DysfunctionCompletedNCT00113113Phase 1

  Sponsor listed in the registry: Astex Pharmaceuticals, Inc. · First submitted before Astex Pharmaceuticals, Inc. became part of Otsuka Holdings Co., Ltd.

• Effect of AT7519M Alone and AT7519M Plus Bortezomib in Patients With Previously Treated Multiple MyelomaCompletedNCT01183949Phase 1/2

  Sponsor listed in the registry: Astex Pharmaceuticals, Inc. · First submitted before Astex Pharmaceuticals, Inc. became part of Otsuka Holdings Co., Ltd.

• Phase II Trial of Decitabine in Patients With Chronic Myelogenous Leukemia Blast Phase Who Are Refractory to Imatinib Mesylate (Gleevec)CompletedNCT00042003Phase 2

  Sponsor listed in the registry: Astex Pharmaceuticals, Inc. · First submitted before Astex Pharmaceuticals, Inc. became part of Otsuka Holdings Co., Ltd.

• Study of SGI-1776, a PIM Kinase Inhibitor, in Subjects With Relapsed/Refractory LeukemiasWithdrawnNCT01239108Phase 1

  Sponsor listed in the registry: Astex Pharmaceuticals, Inc. · First submitted before Astex Pharmaceuticals, Inc. became part of Otsuka Holdings Co., Ltd.

• Study to Assess the Safety of Escalating Doses of AT13387 in Patients With Metastatic Solid TumorsCompletedNCT00878423Phase 1

  Sponsor listed in the registry: Astex Pharmaceuticals, Inc. · First submitted before Astex Pharmaceuticals, Inc. became part of Otsuka Holdings Co., Ltd.

• A Phase 1 Study to Evaluate the Effect of Food on Pharmacokinetics of ASTX029CompletedNCT04466514Phase 1

  Sponsor listed in the registry: Astex Pharmaceuticals, Inc. · First submitted after Astex Pharmaceuticals, Inc. became part of Otsuka Holdings Co., Ltd.

• Effect of Food on the Pharmacokinetics of ASTX660 in Healthy VolunteersCompletedNCT04479800Phase 1

  Sponsor listed in the registry: Astex Pharmaceuticals, Inc. · First submitted after Astex Pharmaceuticals, Inc. became part of Otsuka Holdings Co., Ltd.

• Study to Assess the Safety of Escalating Doses of AT9283, in Patients With LeukemiasTerminatedNCT00522990Phase 1/2

  Sponsor listed in the registry: Astex Pharmaceuticals, Inc. · First submitted before Astex Pharmaceuticals, Inc. became part of Otsuka Holdings Co., Ltd.

• A Study to Investigate the Safety and Efficacy of AT13387, Alone or in Combination With Imatinib, in Patients With GISTCompletedNCT01294202Phase 2

  Sponsor listed in the registry: Astex Pharmaceuticals, Inc. · First submitted before Astex Pharmaceuticals, Inc. became part of Otsuka Holdings Co., Ltd.

• A Study of TAS1553 in Subjects With Relapsed or Refractory Acute Myeloid Leukemia (AML) and Other Myeloid NeoplasmsTerminatedNCT04637009Phase 1

  Sponsor listed in the registry: Astex Pharmaceuticals, Inc. · First submitted after Astex Pharmaceuticals, Inc. became part of Otsuka Holdings Co., Ltd.

• Orathecin + Gemcitabine Versus Placebo + Gemcitabine in Chemonaive Non-Resectable Pancreatic CancerTerminatedNCT00113256Phase 2/3

  Sponsor listed in the registry: Astex Pharmaceuticals, Inc. · First submitted before Astex Pharmaceuticals, Inc. became part of Otsuka Holdings Co., Ltd.

• Nitrocamptothecin in Treating Patients With Locally Recurrent or Metastatic Breast CancerCompletedNCT00005873Phase 2

  Sponsor listed in the registry: Astex Pharmaceuticals, Inc. · First submitted before Astex Pharmaceuticals, Inc. became part of Otsuka Holdings Co., Ltd.

• Nitrocamptothecin in Treating Patients With Soft Tissue SarcomasCompletedNCT00005874Phase 2

  Sponsor listed in the registry: Astex Pharmaceuticals, Inc. · First submitted before Astex Pharmaceuticals, Inc. became part of Otsuka Holdings Co., Ltd.

• Nitrocamptothecin in Treating Patients With Locally Advanced or Metastatic Stomach Cancer That Cannot Be Removed During SurgeryStatus unknownNCT00005876Phase 2

  Sponsor listed in the registry: Astex Pharmaceuticals, Inc. · First submitted before Astex Pharmaceuticals, Inc. became part of Otsuka Holdings Co., Ltd.

• Nitrocamptothecin Compared With Gemcitabine in Treating Patients With Unresectable Locally Advanced or Metastatic Pancreatic CancerStatus unknownNCT00005869Phase 3

  Sponsor listed in the registry: Astex Pharmaceuticals, Inc. · First submitted before Astex Pharmaceuticals, Inc. became part of Otsuka Holdings Co., Ltd.

• Nitrocamptothecin in Treating Patients With Recurrent Non-small Cell Lung CancerCompletedNCT00005872Phase 2

  Sponsor listed in the registry: Astex Pharmaceuticals, Inc. · First submitted before Astex Pharmaceuticals, Inc. became part of Otsuka Holdings Co., Ltd.

• Nitrocamptothecin in Treating Patients With Metastatic MelanomaCompletedNCT00005875Phase 2

  Sponsor listed in the registry: Astex Pharmaceuticals, Inc. · First submitted before Astex Pharmaceuticals, Inc. became part of Otsuka Holdings Co., Ltd.

• Nitrocamptothecin Compared With Other Chemotherapy in Treating Patients With Recurrent or Refractory Cancer of the PancreasStatus unknownNCT00005870Phase 3

  Sponsor listed in the registry: Astex Pharmaceuticals, Inc. · First submitted before Astex Pharmaceuticals, Inc. became part of Otsuka Holdings Co., Ltd.

• Nitrocamptothecin in Treating Patients With Advanced or Recurrent Colorectal CancerStatus unknownNCT00005877Phase 2

  Sponsor listed in the registry: Astex Pharmaceuticals, Inc. · First submitted before Astex Pharmaceuticals, Inc. became part of Otsuka Holdings Co., Ltd.

• Nitrocamptothecin or Fluorouracil in Treating Patients With Recurrent or Refractory Pancreatic CancerStatus unknownNCT00005871Phase 3

  Sponsor listed in the registry: Astex Pharmaceuticals, Inc. · First submitted before Astex Pharmaceuticals, Inc. became part of Otsuka Holdings Co., Ltd.

• MP470 in Treating Patients With Unresectable or Metastatic Solid Tumor or LymphomaTerminatedNCT00504205Not applicable

  Sponsor listed in the registry: Astex Pharmaceuticals, Inc. · First submitted before Astex Pharmaceuticals, Inc. became part of Otsuka Holdings Co., Ltd.

• Phase II Trial of Decitabine in Patients With Chronic Myelogenous Leukemia Chronic Phase Who Are Refractory to Imatinib Mesylate (Gleevec)CompletedNCT00042016Phase 2

  Sponsor listed in the registry: Astex Pharmaceuticals, Inc. · First submitted before Astex Pharmaceuticals, Inc. became part of Otsuka Holdings Co., Ltd.

• Phase II Trial of Decitabine in Patients With Chronic Myelogenous Leukemia Accelerated Phase Who Are Refractory to Imatinib Mesylate (Gleevec)CompletedNCT00041990Phase 2

  Sponsor listed in the registry: Astex Pharmaceuticals, Inc. · First submitted before Astex Pharmaceuticals, Inc. became part of Otsuka Holdings Co., Ltd.